Balaji Prasad
Stock Analyst at Barclays
(3.57)
# 873
Out of 5,117 analysts
147
Total ratings
50%
Success rate
5.67%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $6.90 | +262.32% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $12.95 | -15.06% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $26.51 | -9.47% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $12.32 | -26.95% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $170.48 | +17.32% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $22.60 | -15.93% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $81.78 | -26.63% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $126.23 | +93.30% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $7.18 | +234.26% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $38.17 | -42.36% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $688.48 | -24.47% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $31.89 | -18.47% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $195.83 | -18.30% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.16 | +20.06% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $5.26 | +242.21% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $4.07 | +145.70% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.33 | +426.32% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $6.90
Upside: +262.32%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $12.95
Upside: -15.06%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $26.51
Upside: -9.47%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $12.32
Upside: -26.95%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $170.48
Upside: +17.32%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $22.60
Upside: -15.93%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $81.78
Upside: -26.63%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $126.23
Upside: +93.30%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $7.18
Upside: +234.26%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $38.17
Upside: -42.36%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $688.48
Upside: -24.47%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $31.89
Upside: -18.47%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $195.83
Upside: -18.30%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.16
Upside: +20.06%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $5.26
Upside: +242.21%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $4.07
Upside: +145.70%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.33
Upside: +426.32%